Search Patents
  • Canine Respiratory Coronavirus (Crcv) Spike Protein, Polymerase and Hemagglutinin/Esterase
    Publication number: 20070248616
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Application
    Filed: July 1, 2003
    Publication date: October 25, 2007
    Inventors: John Brownlie, Victoria Chalker, Kerstin Erles
  • Canine respiratory coronavirus (CRCV) spike protein
    Patent number: 7981427
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: July 19, 2011
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • ORAL CORONAVIRUS INFECTION VACCINE
    Publication number: 20240091342
    Abstract: Provided is an orally administrable vaccine against a coronavirus infectious disease. A transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium enables the provision of the orally administrable vaccine against a coronavirus infectious disease. The transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium can induce humoral immunity and cellular immunity through oral administration to suppress an increase in severity of pneumonia or the like even after viral infection.
    Type: Application
    Filed: January 25, 2022
    Publication date: March 21, 2024
    Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Kyoto University
    Inventors: Toshiro SHIRAKAWA, Shunpei UENO, Koichi KITAGAWA, Akihiko KONDO, Masanori KAMEOKA, Takane KATAYAMA
  • CORONAVIRUS VACCINE
    Publication number: 20220218815
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: November 15, 2021
    Publication date: July 14, 2022
    Applicant: CureVac AG
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • Compositions and methods for detecting severe acute respiratory syndrome coronavirus
    Publication number: 20050095582
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: November 3, 2003
    Publication date: May 5, 2005
    Applicants: Diagnostic Hybrids, Inc., Health Research Incorporated
    Inventors: Laura Gillim-Ross, Jill Taylor, David Scholl, David Wentworth, Joseph Jollick
  • Ribozyme to cleave coronavirus gene
    Publication number: 20100273997
    Abstract: Provided is a ribozyme to cleave a coronavirus gene and a therapeutic agent for a coronavirus infectious disease. A common base sequence in coronaviruses such as SARS-CoV and MHV was searched to design a ribozyme including a base sequence complementary thereto. Moreover, a therapeutic agent for a coronavirus infectious disease including such ribozyme was obtained.
    Type: Application
    Filed: August 9, 2006
    Publication date: October 28, 2010
    Inventors: Noboru Fukuda, Takahiro Ueno, Akiko Fukushima, Kazumichi Kuroda
  • Methods and compositions for infectious cDNA of SARS coronavirus
    Publication number: 20060240530
    Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.
    Type: Application
    Filed: January 19, 2006
    Publication date: October 26, 2006
    Inventors: Ralph Baric, Rhonda Roberts, Boyd Yount, Kristopher Curtis
  • CORONAVIRUS VACCINE
    Publication number: 20240000921
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
    Type: Application
    Filed: June 26, 2023
    Publication date: January 4, 2024
    Inventors: Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin, Kayvon Modjarrad
  • CORONAVIRUS VACCINE
    Publication number: 20220395570
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: August 9, 2022
    Publication date: December 15, 2022
    Applicant: CureVac AG
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • CORONAVIRUS VACCINE
    Publication number: 20210379181
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: April 15, 2021
    Publication date: December 9, 2021
    Applicant: CureVac AG
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • Compositions And Methods For Detecting Severe Acute Respiratory Syndrome Coronavirus
    Publication number: 20110223659
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: December 7, 2010
    Publication date: September 15, 2011
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • CORONAVIRUS VACCINE
    Publication number: 20230293672
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: March 6, 2023
    Publication date: September 21, 2023
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • CORONAVIRUS VACCINE
    Publication number: 20230302122
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: June 1, 2023
    Publication date: September 28, 2023
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • Compositions and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus
    Publication number: 20080076115
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: November 3, 2004
    Publication date: March 27, 2008
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • Coronavirus vaccine
    Patent number: 11241493
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: February 8, 2022
    Assignee: CUREVAC AG
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS
    Publication number: 20210267952
    Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.
    Type: Application
    Filed: February 19, 2021
    Publication date: September 2, 2021
    Inventors: ERIC HOLMES, GARY OSTRANDER, GEOFFREY STUART DOW
  • CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220127615
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.
    Type: Application
    Filed: November 10, 2021
    Publication date: April 28, 2022
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp
  • TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS
    Publication number: 20220339140
    Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.
    Type: Application
    Filed: May 24, 2022
    Publication date: October 27, 2022
    Inventors: ERIC HOLMES, GARY OSTRANDER, GEOFFREY STUART DOW
  • NOVEL CORONAVIRUS RAPID DETECTION KIT BASED ON THERMAL CONVECTION PCR
    Publication number: 20230203575
    Abstract: The present invention provides a novel coronavirus rapid detection kit based on thermal convection PCR and a method for multiple detection of novel coronavirus nucleic acid. The kit comprises a combination of primers and probes for detecting N genes and ORFlab genes of a novel coronavirus genome.
    Type: Application
    Filed: November 10, 2020
    Publication date: June 29, 2023
    Inventors: Xiwen JIANG, Taosheng HUANG, Zhuojian LU, Qixian CHEN, Weiping LIN
  • CORONAVIRUS VACCINE
    Publication number: 20220193226
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: CureVac AG
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
Narrow Results

Filter by US Classification